Which has preferable earnings & valuation, NXTC or PPBT?

NextCure is trading at a lower price-to-earnings ratio than Purple Biotech, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio NextCure N/A N/A -$55.84M -$17.19 N/A Purple Biotech N/A N/A -$26.39M -$18.84 N/A

Is NXTC or PPBT more profitable?

Purple Biotech's return on equity of -123.63% beat NextCure's return on equity. Company Net Margins Return on Equity Return on Assets NextCure N/A -186.96% -124.62% Purple Biotech N/A -123.63% -98.72%

Do analysts recommend CDIO or PPBT?

Purple Biotech has a consensus target price of $30.00, indicating a potential upside of 1,685.71%. Given Purple Biotech's stronger consensus rating and higher possible upside, analysts clearly believe Purple Biotech is more favorable than Cardio Diagnostics. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Cardio Diagnostics 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Purple Biotech 1 Sell rating(s) 1 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00

Which has better valuation & earnings, CNSP or PPBT?

CNS Pharmaceuticals is trading at a lower price-to-earnings ratio than Purple Biotech, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio CNS Pharmaceuticals N/A N/A -$15.85M -$29.63 N/A Purple Biotech N/A N/A -$26.39M -$18.84 N/A

Is CNSP or PPBT more profitable?

Purple Biotech's return on equity of -123.63% beat CNS Pharmaceuticals' return on equity. Company Net Margins Return on Equity Return on Assets CNS Pharmaceuticals N/A -238.68% -166.30% Purple Biotech N/A -123.63% -98.72%

Which has preferable earnings and valuation, ACXP or PPBT?

Acurx Pharmaceuticals is trading at a lower price-to-earnings ratio than Purple Biotech, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Acurx Pharmaceuticals N/A N/A -$7.97M -$4.05 N/A Purple Biotech N/A N/A -$26.39M -$18.84 N/A

Is ACXP or PPBT more profitable?

Purple Biotech's return on equity of -123.63% beat Acurx Pharmaceuticals' return on equity. Company Net Margins Return on Equity Return on Assets Acurx Pharmaceuticals N/A -153.92% -101.69% Purple Biotech N/A -123.63% -98.72%

Is PPBT or BCAB more profitable?

BioAtla's return on equity of 0.00% beat Purple Biotech's return on equity. Company Net Margins Return on Equity Return on Assets Purple Biotech N/A -123.63% -98.72% BioAtla N/A N/A -325.64%

Purple Biotech (PPBT) Competitors

$1.68 -0.06 (-3.45%)

Closing price 06/30/2026 04:00 PM Eastern

Extended Trading

$1.70 +0.02 (+1.25%)

As of 08:58 AM Eastern

Compare

PPBT vs. NXTC, CDIO, CNSP, ACXP, and BCAB

Should you buy Purple Biotech stock or one of its competitors? MarketBeat compares Purple Biotech with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Purple Biotech include NextCure (NXTC), Cardio Diagnostics (CDIO), CNS Pharmaceuticals (CNSP), Acurx Pharmaceuticals (ACXP), and BioAtla (BCAB). These companies are all part of the "pharmaceutical products" industry.

How does Purple Biotech compare to NextCure?

NextCure (NASDAQ:NXTC) and Purple Biotech (NASDAQ:PPBT) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their valuation, analyst recommendations, institutional ownership, media sentiment, earnings, dividends, profitability and risk.

Purple Biotech's return on equity of -123.63% beat NextCure's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
NextCure	N/A	-186.96%	-124.62%
Purple Biotech	N/A	-123.63%	-98.72%

42.7% of NextCure shares are held by institutional investors. Comparatively, 9.6% of Purple Biotech shares are held by institutional investors. 11.9% of NextCure shares are held by company insiders. Comparatively, 3.0% of Purple Biotech shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

NextCure is trading at a lower price-to-earnings ratio than Purple Biotech, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
NextCure	N/A	N/A	-$55.84M	-$17.19	N/A
Purple Biotech	N/A	N/A	-$26.39M	-$18.84	N/A

In the previous week, NextCure had 2 more articles in the media than Purple Biotech. MarketBeat recorded 4 mentions for NextCure and 2 mentions for Purple Biotech. NextCure's average media sentiment score of 0.47 beat Purple Biotech's score of 0.43 indicating that NextCure is being referred to more favorably in the media.

Company	Overall Sentiment
NextCure	Neutral
Purple Biotech	Neutral

NextCure presently has a consensus target price of $16.50, indicating a potential upside of 931.25%. Purple Biotech has a consensus target price of $30.00, indicating a potential upside of 1,685.71%. Given Purple Biotech's higher probable upside, analysts clearly believe Purple Biotech is more favorable than NextCure.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
NextCure	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.25
Purple Biotech	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

NextCure has a beta of 1.3, indicating that its stock price is 30% more volatile than the broader market. Comparatively, Purple Biotech has a beta of 0.61, indicating that its stock price is 39% less volatile than the broader market.

Summary

NextCure beats Purple Biotech on 8 of the 13 factors compared between the two stocks.

How does Purple Biotech compare to Cardio Diagnostics?

Cardio Diagnostics (NASDAQ:CDIO) and Purple Biotech (NASDAQ:PPBT) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their institutional ownership, earnings, media sentiment, valuation, dividends, profitability, risk and analyst recommendations.

Cardio Diagnostics has a beta of 2.24, suggesting that its stock price is 124% more volatile than the broader market. Comparatively, Purple Biotech has a beta of 0.61, suggesting that its stock price is 39% less volatile than the broader market.

Cardio Diagnostics has higher revenue and earnings than Purple Biotech. Cardio Diagnostics is trading at a lower price-to-earnings ratio than Purple Biotech, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Cardio Diagnostics	$10K	648.24	-$6.50M	-$3.38	N/A
Purple Biotech	N/A	N/A	-$26.39M	-$18.84	N/A

In the previous week, Cardio Diagnostics had 5 more articles in the media than Purple Biotech. MarketBeat recorded 7 mentions for Cardio Diagnostics and 2 mentions for Purple Biotech. Purple Biotech's average media sentiment score of 0.43 beat Cardio Diagnostics' score of 0.09 indicating that Purple Biotech is being referred to more favorably in the news media.

Company	Overall Sentiment
Cardio Diagnostics	Neutral
Purple Biotech	Neutral

Purple Biotech has a consensus target price of $30.00, indicating a potential upside of 1,685.71%. Given Purple Biotech's stronger consensus rating and higher possible upside, analysts clearly believe Purple Biotech is more favorable than Cardio Diagnostics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Cardio Diagnostics	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Purple Biotech	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

8.1% of Cardio Diagnostics shares are owned by institutional investors. Comparatively, 9.6% of Purple Biotech shares are owned by institutional investors. 13.3% of Cardio Diagnostics shares are owned by company insiders. Comparatively, 3.0% of Purple Biotech shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Purple Biotech has a net margin of 0.00% compared to Cardio Diagnostics' net margin of -36,950.00%. Cardio Diagnostics' return on equity of -78.82% beat Purple Biotech's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Cardio Diagnostics	-36,950.00%	-78.82%	-72.87%
Purple Biotech	N/A	-123.63%	-98.72%

Summary

Cardio Diagnostics beats Purple Biotech on 8 of the 15 factors compared between the two stocks.

How does Purple Biotech compare to CNS Pharmaceuticals?

CNS Pharmaceuticals (NASDAQ:CNSP) and Purple Biotech (NASDAQ:PPBT) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their dividends, media sentiment, risk, institutional ownership, analyst recommendations, earnings, valuation and profitability.

14.0% of CNS Pharmaceuticals shares are held by institutional investors. Comparatively, 9.6% of Purple Biotech shares are held by institutional investors. 0.0% of CNS Pharmaceuticals shares are held by company insiders. Comparatively, 3.0% of Purple Biotech shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

CNS Pharmaceuticals is trading at a lower price-to-earnings ratio than Purple Biotech, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
CNS Pharmaceuticals	N/A	N/A	-$15.85M	-$29.63	N/A
Purple Biotech	N/A	N/A	-$26.39M	-$18.84	N/A

In the previous week, Purple Biotech had 1 more articles in the media than CNS Pharmaceuticals. MarketBeat recorded 2 mentions for Purple Biotech and 1 mentions for CNS Pharmaceuticals. CNS Pharmaceuticals' average media sentiment score of 1.89 beat Purple Biotech's score of 0.43 indicating that CNS Pharmaceuticals is being referred to more favorably in the media.

Company	Overall Sentiment
CNS Pharmaceuticals	Very Positive
Purple Biotech	Neutral

CNS Pharmaceuticals has a beta of 3.06, meaning that its share price is 206% more volatile than the broader market. Comparatively, Purple Biotech has a beta of 0.61, meaning that its share price is 39% less volatile than the broader market.

CNS Pharmaceuticals currently has a consensus target price of $20.00, indicating a potential upside of 318.41%. Purple Biotech has a consensus target price of $30.00, indicating a potential upside of 1,685.71%. Given Purple Biotech's higher probable upside, analysts plainly believe Purple Biotech is more favorable than CNS Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
CNS Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Purple Biotech	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

Purple Biotech's return on equity of -123.63% beat CNS Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
CNS Pharmaceuticals	N/A	-238.68%	-166.30%
Purple Biotech	N/A	-123.63%	-98.72%

Summary

Purple Biotech beats CNS Pharmaceuticals on 7 of the 11 factors compared between the two stocks.

How does Purple Biotech compare to Acurx Pharmaceuticals?

Acurx Pharmaceuticals (NASDAQ:ACXP) and Purple Biotech (NASDAQ:PPBT) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their profitability, earnings, valuation, institutional ownership, dividends, media sentiment, analyst recommendations and risk.

Purple Biotech's return on equity of -123.63% beat Acurx Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Acurx Pharmaceuticals	N/A	-153.92%	-101.69%
Purple Biotech	N/A	-123.63%	-98.72%

Acurx Pharmaceuticals presently has a consensus price target of $31.00, indicating a potential upside of 1,900.00%. Purple Biotech has a consensus price target of $30.00, indicating a potential upside of 1,685.71%. Given Acurx Pharmaceuticals' higher probable upside, equities research analysts plainly believe Acurx Pharmaceuticals is more favorable than Purple Biotech.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Acurx Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Purple Biotech	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

Acurx Pharmaceuticals is trading at a lower price-to-earnings ratio than Purple Biotech, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Acurx Pharmaceuticals	N/A	N/A	-$7.97M	-$4.05	N/A
Purple Biotech	N/A	N/A	-$26.39M	-$18.84	N/A

In the previous week, Purple Biotech had 1 more articles in the media than Acurx Pharmaceuticals. MarketBeat recorded 2 mentions for Purple Biotech and 1 mentions for Acurx Pharmaceuticals. Acurx Pharmaceuticals' average media sentiment score of 1.89 beat Purple Biotech's score of 0.43 indicating that Acurx Pharmaceuticals is being referred to more favorably in the media.

Company	Overall Sentiment
Acurx Pharmaceuticals	Very Positive
Purple Biotech	Neutral

11.5% of Acurx Pharmaceuticals shares are held by institutional investors. Comparatively, 9.6% of Purple Biotech shares are held by institutional investors. 20.3% of Acurx Pharmaceuticals shares are held by insiders. Comparatively, 3.0% of Purple Biotech shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Acurx Pharmaceuticals has a beta of -2.09, suggesting that its share price is 309% less volatile than the broader market. Comparatively, Purple Biotech has a beta of 0.61, suggesting that its share price is 39% less volatile than the broader market.

Summary

Acurx Pharmaceuticals beats Purple Biotech on 6 of the 11 factors compared between the two stocks.

How does Purple Biotech compare to BioAtla?

Purple Biotech (NASDAQ:PPBT) and BioAtla (NASDAQ:BCAB) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their media sentiment, institutional ownership, dividends, analyst recommendations, profitability, earnings, valuation and risk.

In the previous week, Purple Biotech had 1 more articles in the media than BioAtla. MarketBeat recorded 2 mentions for Purple Biotech and 1 mentions for BioAtla. BioAtla's average media sentiment score of 1.87 beat Purple Biotech's score of 0.43 indicating that BioAtla is being referred to more favorably in the news media.

Company	Overall Sentiment
Purple Biotech	Neutral
BioAtla	Very Positive

Purple Biotech presently has a consensus target price of $30.00, indicating a potential upside of 1,685.71%. BioAtla has a consensus target price of $200.00, indicating a potential upside of 4,730.92%. Given BioAtla's higher possible upside, analysts clearly believe BioAtla is more favorable than Purple Biotech.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Purple Biotech	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
BioAtla	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

Purple Biotech has higher earnings, but lower revenue than BioAtla. BioAtla is trading at a lower price-to-earnings ratio than Purple Biotech, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Purple Biotech	N/A	N/A	-$26.39M	-$18.84	N/A
BioAtla	$2M	3.44	-$59.61M	-$41.72	N/A

9.6% of Purple Biotech shares are owned by institutional investors. Comparatively, 77.2% of BioAtla shares are owned by institutional investors. 3.0% of Purple Biotech shares are owned by company insiders. Comparatively, 9.3% of BioAtla shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

BioAtla's return on equity of 0.00% beat Purple Biotech's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Purple Biotech	N/A	-123.63%	-98.72%
BioAtla	N/A	N/A	-325.64%

Purple Biotech has a beta of 0.61, indicating that its share price is 39% less volatile than the broader market. Comparatively, BioAtla has a beta of 0.79, indicating that its share price is 21% less volatile than the broader market.

Summary

BioAtla beats Purple Biotech on 7 of the 12 factors compared between the two stocks.

Get Purple Biotech News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding PPBT and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

PPBT vs. The Competition

Export

Metric	Purple Biotech	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$1.62M	$3.66B	$7.07B	$12.45B
Dividend Yield	N/A	2.20%	2.66%	6.16%
P/E Ratio	-0.09	20.90	27.24	24.87
Price / Sales	N/A	341.80	542.17	102.84
Price / Cash	N/A	143.77	48.53	58.59
Price / Book	0.16	8.75	10.95	6.54
Net Income	-$26.39M	$23.81M	$3.57B	$336.70M
7 Day Performance	-4.00%	3.60%	2.27%	2.81%
1 Month Performance	-43.81%	3.72%	1.35%	0.59%
1 Year Performance	-92.94%	68.80%	36.71%	31.29%

Purple Biotech Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
PPBT Purple Biotech	2.4002 of 5 stars	$1.68 -3.4%	$30.00 +1,685.7%	-92.9%	$1.62M	N/A	N/A	20	Short Interest Increase
NXTC NextCure	2.5433 of 5 stars	$1.81 +3.4%	$23.00 +1,170.7%	-71.0%	$6.53M	N/A	N/A	90	News Coverage Short Interest Increase Gap Down High Trading Volume
CDIO Cardio Diagnostics	0.7648 of 5 stars	$2.18 +10.7%	N/A	-39.2%	$6.45M	$10K	N/A	1	News Coverage Gap Down
CNSP CNS Pharmaceuticals	3.91 of 5 stars	$4.29 +0.2%	$20.00 +366.2%	-51.7%	$6.27M	N/A	N/A	5
ACXP Acurx Pharmaceuticals	3.2382 of 5 stars	$1.42 -6.0%	$31.00 +2,083.1%	-84.8%	$6.11M	N/A	N/A	3

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:PPBT) was last updated on 7/1/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Purple Biotech (PPBT) Competitors

PPBT vs. NXTC, CDIO, CNSP, ACXP, and BCAB

How does Purple Biotech compare to NextCure?

Summary

How does Purple Biotech compare to Cardio Diagnostics?

Summary

How does Purple Biotech compare to CNS Pharmaceuticals?

Summary

How does Purple Biotech compare to Acurx Pharmaceuticals?

Summary

How does Purple Biotech compare to BioAtla?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

PPBT vs. The Competition

Purple Biotech Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Purple Biotech (PPBT) Competitors

PPBT vs. NXTC, CDIO, CNSP, ACXP, and BCAB

How does Purple Biotech compare to NextCure?

Is NXTC or PPBT more profitable?

Do insiders and institutionals believe in NXTC or PPBT?

Which has preferable earnings & valuation, NXTC or PPBT?

Does the media favor NXTC or PPBT?

Do analysts prefer NXTC or PPBT?

Which has more volatility and risk, NXTC or PPBT?

Summary

How does Purple Biotech compare to Cardio Diagnostics?

Which has more volatility and risk, CDIO or PPBT?

Which has preferable valuation & earnings, CDIO or PPBT?

Does the media prefer CDIO or PPBT?

Do analysts recommend CDIO or PPBT?

Do institutionals and insiders have more ownership in CDIO or PPBT?

Is CDIO or PPBT more profitable?

Summary

How does Purple Biotech compare to CNS Pharmaceuticals?

Do insiders & institutionals have more ownership in CNSP or PPBT?

Which has better valuation & earnings, CNSP or PPBT?

Does the media prefer CNSP or PPBT?

Which has more risk & volatility, CNSP or PPBT?

Do analysts rate CNSP or PPBT?

Is CNSP or PPBT more profitable?

Summary

How does Purple Biotech compare to Acurx Pharmaceuticals?

Is ACXP or PPBT more profitable?

Do analysts prefer ACXP or PPBT?

Which has preferable earnings and valuation, ACXP or PPBT?

Does the media prefer ACXP or PPBT?

Do institutionals and insiders believe in ACXP or PPBT?

Which has more risk and volatility, ACXP or PPBT?

Summary

How does Purple Biotech compare to BioAtla?

Does the media favor PPBT or BCAB?

Do analysts recommend PPBT or BCAB?

Which has better earnings and valuation, PPBT or BCAB?

Do insiders and institutionals have more ownership in PPBT or BCAB?

Is PPBT or BCAB more profitable?

Which has more volatility & risk, PPBT or BCAB?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

PPBT vs. The Competition

Purple Biotech Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools